Key Considerations for the Management of RSV in Adult Patients
A panel of experts have a comprehensive discussion on RSV, highlighting risk factors, complications, and the benefits of vaccination.
Episodes
June 24th 2024EP. 1: Overview of RSV Patient Populations
A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.
June 24th 2024EP. 2: Complications Associated with RSV Infections
Marty J. Feltner, PharmD, provides insights on complications associated with RSV infections and how complications vary for different patient populations.
July 1st 2024EP. 3: The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV
Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.
July 1st 2024EP. 4: RSV: Risk Factors and How It’s Spread
A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.
July 8th 2024EP. 5: Diagnostic Practices for RSV
Focusing on the diagnosis of RSV, Mary Bridgeman, PharmD, BCPS, BCGP, provides clinical insights on signs and symptoms and testing practices.
July 8th 2024EP. 6: Increasing Awareness of RSV Vaccines in At-Risk Patients
The expert panel discusses ways to increase awareness of the RSV vaccine for patients who would benefit from it.
July 15th 2024EP. 7: Shared Decision-Making Practices in RSV
Experts on RSV vaccination discuss shared decision-making practices and the importance of getting at-risk patients vaccinated.
July 15th 2024EP. 8: Financial and Clinical Benefits of RSV Immunization
Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.
July 22nd 2024EP. 9: The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
July 22nd 2024EP. 10: Addressing Vaccine Fatigue
Mary Bridgeman, PharmD, BCPS, BCGP, discusses how providers and healthcare workers can address vaccine fatigue in patients eligible for the RSV vaccine.
July 29th 2024EP. 11: Identifying Patients Eligible for RSV Vaccine
Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.
July 29th 2024EP. 12: Current and Potential Obstacles Related to Administering RSV Vaccines
An internal medicine pharmacist discusses current and potential obstacles related to administering RSV vaccines to patients from different age groups.
August 5th 2024EP. 13: Improving Insurance Coverage for RSV Vaccines
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
August 5th 2024EP. 14: Improving RSV Vaccination Rates and Addressing Misinformation
Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.
August 5th 2024EP. 15: Key Takeaways on RSV Vaccination
The panel concludes its discussion by providing key takeaways on the evolving RSV vaccination landscape.
